Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma
ChiCTR1900028646Phase 4Recruiting
- Sponsor
- Nanyang Central Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Nanyang Central Hospital. Primary endpoint: Progression-free survival time. Started Dec 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900028646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028646.